Crossmark

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

Crossref DOI link: https://doi.org/10.1007/s40744-018-0106-6

Published Online: 2018-03-31

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nash, Peter

McInnes, Iain B.

Mease, Philip J.

Thom, Howard

Hunger, Matthias

Karabis, Andreas

Gandhi, Kunal

Mpofu, Shephard

Jugl, Steffen M.
Funding

Funding for this research was provided by:

Novartis
License Information

Text and Data Mining valid from 2018-03-31
More Information

Article History

Received: 3 January 2018

First Online: 31 March 2018

Change Date: 1 June 2018

Change Type: Correction

Change Details: Under Methods section, heading Analyses: Pairwise Comparisons, one of the probability value was published incorrectly in a sentence. The correct sentence should read as follows.